J Thomas Roland1, Bruce J Gantz2, Susan B Waltzman1, Aaron J Parkinson3. 1. Department of Otolaryngology-Head and Neck Surgery, NYU School of Medicine, New York, New York. 2. Department of Otolaryngology-Head and Neck Surgery, the University of Iowa, Iowa City, Iowa. 3. Cochlear Americas, Centennial, Colorado, U.S.A.
Abstract
OBJECTIVE: To demonstrate the long-term benefits of implantation in patients with high-frequency sensorineural hearing loss, this report provides 5-year follow-up on a group of implant recipients who were subjects of the Cochlear™ Nucleus® Hybrid™ L24 Implant System pivotal clinical study. METHODS: The results of three related clinical studies were compiled to provide outcome data after 1, 3, and 5 years of implant use in a group of subjects who presented with preoperative high-frequency hearing loss and were implanted with a Nucleus Hybrid L24 (Cochlear Ltd., Sydney, Australia) cochlear implant. A subset of the 50 adult subjects (N = 32) who participated in the Hybrid L24 pivotal Investigational Device Exemption (IDE) completed comprehensive evaluations at 12 months postactivation, 3 years postactivation, and then as part of a postapproval study at 5 years postactivation. Testing included audiometric, speech perception, and subjective satisfaction measures. RESULTS: Mean unilateral speech perception performance was significantly improved at all postoperative intervals compared to preoperative best-aided results and has remained stable to 5 years postactivation. Ninety-four percent of subjects had measurable hearing, and 72% continued to use electric-acoustic stimulation in the implanted ear after 5 years of implant use. Subjective satisfaction results support objective performance improvements. CONCLUSION: Results demonstrate long-term success of patients with high-frequency hearing loss following Hybrid L24 (Cochlear) cochlear implantation. Benefits include speech perception abilities significantly better than those in the preoperative best-aided condition, with additional benefit in those using electric-acoustic stimulation in the implanted ear. LEVEL OF EVIDENCE: 2b. Laryngoscope, 1939-1945, 2018.
OBJECTIVE: To demonstrate the long-term benefits of implantation in patients with high-frequency sensorineural hearing loss, this report provides 5-year follow-up on a group of implant recipients who were subjects of the Cochlear™ Nucleus® Hybrid™ L24 Implant System pivotal clinical study. METHODS: The results of three related clinical studies were compiled to provide outcome data after 1, 3, and 5 years of implant use in a group of subjects who presented with preoperative high-frequency hearing loss and were implanted with a Nucleus Hybrid L24 (Cochlear Ltd., Sydney, Australia) cochlear implant. A subset of the 50 adult subjects (N = 32) who participated in the Hybrid L24 pivotal Investigational Device Exemption (IDE) completed comprehensive evaluations at 12 months postactivation, 3 years postactivation, and then as part of a postapproval study at 5 years postactivation. Testing included audiometric, speech perception, and subjective satisfaction measures. RESULTS: Mean unilateral speech perception performance was significantly improved at all postoperative intervals compared to preoperative best-aided results and has remained stable to 5 years postactivation. Ninety-four percent of subjects had measurable hearing, and 72% continued to use electric-acoustic stimulation in the implanted ear after 5 years of implant use. Subjective satisfaction results support objective performance improvements. CONCLUSION: Results demonstrate long-term success of patients with high-frequency hearing loss following Hybrid L24 (Cochlear) cochlear implantation. Benefits include speech perception abilities significantly better than those in the preoperative best-aided condition, with additional benefit in those using electric-acoustic stimulation in the implanted ear. LEVEL OF EVIDENCE: 2b. Laryngoscope, 1939-1945, 2018.
Authors: Frank R Lin; Wade W Chien; Lingsheng Li; Danisa M Clarrett; John K Niparko; Howard W Francis Journal: Medicine (Baltimore) Date: 2012-09 Impact factor: 1.889
Authors: Henryk Skarzynski; Artur Lorens; Monika Matusiak; Marek Porowski; Piotr H Skarzynski; Chris J James Journal: Audiol Neurootol Date: 2011-08-12 Impact factor: 1.854
Authors: Kathryn M Van Abel; Camille C Dunn; Douglas P Sladen; Jacob J Oleson; Charles W Beatty; Brian A Neff; Marlan Hansen; Bruce J Gantz; Colin L W Driscoll Journal: Otol Neurotol Date: 2015-03 Impact factor: 2.311
Authors: Bruce J Gantz; Marlan R Hansen; Christopher W Turner; Jacob J Oleson; Lina A Reiss; Aaron J Parkinson Journal: Audiol Neurootol Date: 2009-04-22 Impact factor: 1.854
Authors: Thomas Lenarz; Andreas Buechner; Bruce Gantz; Marlan Hansen; Viral D Tejani; Robert Labadie; Brendan O'Connell; Craig Alan Buchman; Carla V Valenzuela; Oliver F Adunka; Michael S Harris; William J Riggs; Douglas Fitzpatrick; Kanthaiah Koka Journal: Otol Neurotol Date: 2022-01-01 Impact factor: 2.311
Authors: Viral D Tejani; Hyejin Yang; Jeong-Seo Kim; Helin Hernandez; Jacob J Oleson; Marlan R Hansen; Bruce J Gantz; Paul J Abbas; Carolyn J Brown Journal: J Assoc Res Otolaryngol Date: 2021-10-22
Authors: Margaret T Dillon; Michael W Canfarotta; Emily Buss; Joseph Hopfinger; Brendan P O'Connell Journal: Otol Neurotol Date: 2021-01 Impact factor: 2.311
Authors: Viral D Tejani; Jeong-Seo Kim; Jacob J Oleson; Paul J Abbas; Carolyn J Brown; Marlan R Hansen; Bruce J Gantz Journal: J Assoc Res Otolaryngol Date: 2021-02-04